Literature DB >> 32613525

Development and Initial Testing of an mHealth Transitions of Care Intervention for Adults with Schizophrenia-Spectrum Disorders Immediately Following a Psychiatric Hospitalization.

Ethan Moitra1, Hyun Seon Park2, Brandon A Gaudiano3,2,4.   

Abstract

An important period in the care of patients with schizophrenia-spectrum disorders is when they transition from inpatient to outpatient services and are at increased risk for relapse and rehospitalization. Thus, we developed and examined the initial feasibility, acceptability, and clinical effects of an mHealth transitions of care intervention (Mobile After-Care Support; MACS) in an open trial. Ten adults with schizophrenia-spectrum disorders were recruited during their index psychiatric hospitalization and enrolled prior to discharge. Measures of feasibility, acceptability, and MACS targets were administered at baseline and a 1-month follow-up. Drawing on skills from Cognitive Behavioral Therapy for Psychosis (CBTp), MACS delivered brief assessments of clinically relevant variables, followed by just-in-time interventions for patients starting immediately post-discharge. Individuals completed about one session per day on average as expected. Overall, measures of MACS usability and satisfaction were positive. T-test analyses showed that dysfunctional coping strategies significantly decreased from baseline to 1-month follow-up. Results also revealed statistically significant reductions in psychiatric symptoms over 1-month follow-up. This study demonstrates the feasibility and acceptability of MACS, a new app-based intervention targeting transitions of care for patients with psychosis. The field is turning to the use of mobile technology as a means of augmenting service delivery and providing real-time assessment and intervention for patients at risk. MACS is a promising adjunctive intervention that warrants further testing in a randomized controlled trial.

Entities:  

Keywords:  Cognitive behavior therapy for psychosis; Mobile technology; Psychiatric hospitalization; Psychosis; Schizophrenia; Treatment adherence

Mesh:

Year:  2021        PMID: 32613525      PMCID: PMC7775867          DOI: 10.1007/s11126-020-09792-9

Source DB:  PubMed          Journal:  Psychiatr Q        ISSN: 0033-2720


  37 in total

1.  Predicting medication noncompliance after hospital discharge among patients with schizophrenia.

Authors:  M Olfson; D Mechanic; S Hansell; C A Boyer; J Walkup; P J Weiden
Journal:  Psychiatr Serv       Date:  2000-02       Impact factor: 3.084

2.  Identifying life stressors of patients with schizophrenia at hospital discharge.

Authors:  David Kimhy; Jill M Harkavy-Friedman; Elizabeth A Nelson
Journal:  Psychiatr Serv       Date:  2004-12       Impact factor: 3.084

Review 3.  Antipsychotic medication adherence in schizophrenia.

Authors:  Matthew J Byerly; Paul A Nakonezny; Emmeline Lescouflair
Journal:  Psychiatr Clin North Am       Date:  2007-09

4.  Time to discontinuation of first- and second-generation antipsychotic medications in the treatment of schizophrenia.

Authors:  Julie Kreyenbuhl; Eric P Slade; Deborah R Medoff; Clayton H Brown; Benjamin Ehrenreich; Joseph Afful; Lisa B Dixon
Journal:  Schizophr Res       Date:  2011-05-14       Impact factor: 4.939

5.  Predictors and clinical consequences of non-adherence with antipsychotic medication in the outpatient treatment of schizophrenia.

Authors:  Diego Novick; Josep Maria Haro; David Suarez; Victor Perez; Ralf W Dittmann; Peter M Haddad
Journal:  Psychiatry Res       Date:  2010-02-24       Impact factor: 3.222

6.  Quality of life and burden in parents of outpatients with schizophrenia.

Authors:  Anniqa Foldemo; Mats Gullberg; Anna-Christina Ek; Lennart Bogren
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2005-02       Impact factor: 4.328

Review 7.  The Societal Cost of Schizophrenia: A Systematic Review.

Authors:  Huajie Jin; Iris Mosweu
Journal:  Pharmacoeconomics       Date:  2017-01       Impact factor: 4.981

8.  Symptom dimensions and functional impairment in early psychosis: more to the story than just negative symptoms.

Authors:  Daniel Fulford; Tara A Niendam; Erin G Floyd; Cameron S Carter; Daniel H Mathalon; Sophia Vinogradov; Barbara K Stuart; Rachel L Loewy
Journal:  Schizophr Res       Date:  2013-04-12       Impact factor: 4.939

9.  Risk of discontinuation of atypical antipsychotic agents in the treatment of schizophrenia.

Authors:  C Daniel Mullins; Nour A Obeidat; Brian J Cuffel; John Naradzay; Antony D Loebel
Journal:  Schizophr Res       Date:  2007-06-26       Impact factor: 4.939

Review 10.  Global economic burden of schizophrenia: a systematic review.

Authors:  Huey Yi Chong; Siew Li Teoh; David Bin-Chia Wu; Surachai Kotirum; Chiun-Fang Chiou; Nathorn Chaiyakunapruk
Journal:  Neuropsychiatr Dis Treat       Date:  2016-02-16       Impact factor: 2.570

View more
  1 in total

1.  Ecological momentary interventions for mental health: A scoping review.

Authors:  Andreas Balaskas; Stephen M Schueller; Anna L Cox; Gavin Doherty
Journal:  PLoS One       Date:  2021-03-11       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.